Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by STEFAN OCTAVIAN CIUREA and CHITRA HOSING.
STEFAN OCTAVIAN CIUREA
Connection Strength
5.087
CHITRA HOSING
  1. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica. 2021 01 01; 106(1):269-274.
    View in: PubMed
    Score: 0.189
  2. Can we cure refractory Hodgkin's lymphoma with transplantation? Bone Marrow Transplant. 2021 01; 56(1):278-281.
    View in: PubMed
    Score: 0.183
  3. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020 02 06; 135(6):449-452.
    View in: PubMed
    Score: 0.178
  4. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.
    View in: PubMed
    Score: 0.174
  5. Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. Am J Hematol. 2019 06; 94(6):E176-E180.
    View in: PubMed
    Score: 0.168
  6. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
    View in: PubMed
    Score: 0.166
  7. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 04; 54(4):601-606.
    View in: PubMed
    Score: 0.163
  8. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018 09 11; 2(17):2254-2261.
    View in: PubMed
    Score: 0.161
  9. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018 06 28; 131(26):2989-2992.
    View in: PubMed
    Score: 0.158
  10. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.151
  11. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 07; 31(7):1654-1657.
    View in: PubMed
    Score: 0.146
  12. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.
    View in: PubMed
    Score: 0.146
  13. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.
    View in: PubMed
    Score: 0.146
  14. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.139
  15. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016 05; 173(3):444-55.
    View in: PubMed
    Score: 0.136
  16. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.
    View in: PubMed
    Score: 0.134
  17. Outcomes of Haploidentical Stem Cell Transplantation for?Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2016 Mar; 22(3):493-8.
    View in: PubMed
    Score: 0.132
  18. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015 Dec; 26(12):2490-5.
    View in: PubMed
    Score: 0.132
  19. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.
    View in: PubMed
    Score: 0.131
  20. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. 2013 Sep; 88(9):754-7.
    View in: PubMed
    Score: 0.113
  21. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.
    View in: PubMed
    Score: 0.105
  22. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012 May; 53(5):901-6.
    View in: PubMed
    Score: 0.102
  23. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr; 16(4):555-9.
    View in: PubMed
    Score: 0.089
  24. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant. 2008 Jul; 42(1):67-9.
    View in: PubMed
    Score: 0.078
  25. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv. 2024 06 25; 8(12):3237-3245.
    View in: PubMed
    Score: 0.060
  26. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024 May; 59(5):699-704.
    View in: PubMed
    Score: 0.059
  27. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 04; 99(4):562-569.
    View in: PubMed
    Score: 0.059
  28. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.
    View in: PubMed
    Score: 0.052
  29. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 12; 27(12):1003.e1-1003.e13.
    View in: PubMed
    Score: 0.050
  30. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021 11; 27(11):913.e1-913.e12.
    View in: PubMed
    Score: 0.049
  31. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
    View in: PubMed
    Score: 0.048
  32. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.
    View in: PubMed
    Score: 0.048
  33. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2021 05 15; 127(10):1598-1605.
    View in: PubMed
    Score: 0.048
  34. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021 06; 56(6):1316-1324.
    View in: PubMed
    Score: 0.047
  35. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.
    View in: PubMed
    Score: 0.047
  36. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
    View in: PubMed
    Score: 0.046
  37. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020 08; 26(8):1439-1445.
    View in: PubMed
    Score: 0.045
  38. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306.
    View in: PubMed
    Score: 0.045
  39. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.
    View in: PubMed
    Score: 0.045
  40. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.
    View in: PubMed
    Score: 0.044
  41. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma. 2019 12; 60(14):3536-3543.
    View in: PubMed
    Score: 0.043
  42. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
    View in: PubMed
    Score: 0.042
  43. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.
    View in: PubMed
    Score: 0.042
  44. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.
    View in: PubMed
    Score: 0.041
  45. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
    View in: PubMed
    Score: 0.041
  46. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 06; 54(6):839-848.
    View in: PubMed
    Score: 0.040
  47. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.039
  48. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50.
    View in: PubMed
    Score: 0.038
  49. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2166-2171.
    View in: PubMed
    Score: 0.038
  50. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.
    View in: PubMed
    Score: 0.037
  51. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292.
    View in: PubMed
    Score: 0.035
  52. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
    View in: PubMed
    Score: 0.035
  53. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma. 2017 02; 58(2):366-371.
    View in: PubMed
    Score: 0.035
  54. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.
    View in: PubMed
    Score: 0.034
  55. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.032
  56. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12.
    View in: PubMed
    Score: 0.031
  57. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1975-81.
    View in: PubMed
    Score: 0.031
  58. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):319-26.
    View in: PubMed
    Score: 0.029
  59. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.
    View in: PubMed
    Score: 0.028
  60. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1059-64.
    View in: PubMed
    Score: 0.028
  61. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013 Mar; 160(6):798-805.
    View in: PubMed
    Score: 0.027
  62. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
    View in: PubMed
    Score: 0.027
  63. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1819-26.
    View in: PubMed
    Score: 0.026
  64. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.
    View in: PubMed
    Score: 0.026
  65. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8.
    View in: PubMed
    Score: 0.026
  66. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar; 53(3):499-502.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.